59 results about "Intestinal mucosal barrier" patented technology

The invention discloses a special nutritional supplement agent for preoperative patients. The nutritional supplement agent contains maltodextrin, levulose, glutamine, sodium ions and potassium ions. When the preoperative nutritional agent is taken, the nutritional agent can be compounded into an isotonic solution of which the osmotic pressure level is similar to that of plasma, so that the possibility of diarrhoea caused by that a great deal of liquid enters intestinal tracts through tissues due to osmotic pressure differences can be obviated; the feeling that an operation patient feels thirsty and tired can be obviously improved, and the symptoms of nausea, vomit, diarrhoea, abdominal distension and the like cannot be caused; complete emptying can be realized within 79-107 minutes, and experiments confirm that taking the nutritional agent for 2 hours before the operation is safe; in addition, the nutritional agent also has good effects of improving insulin resistance and maintaining intestinal mucosal barriers.

The invention discloses a nutriment for improving the immunity of patients suffering from tumors after operation, radiotherapy and chemotherapy and a preparation method of the nutriment, and belongs to the technical field of medical foods. The nutriment comprises 45-98g/L of protein, 22-48g/L of fat, 98-245g/L of carbohydrate, 0-18g/L of dietary fibers, 0.35-0.75g/L of vitamins, 3.6-7.2g/L of trace elements, 1.0-2.2g/L of nucleotide, 0.2-20g/L of arginine, 0-0.2g/L of taurine, and an appropriate amount of water. The nutriment has various nutrient components, is rich in glutamine, arginine, nucleotide, omega-stability fatty acid and the like, is scientific in proportion, improves the nutritional status of patients, improves the resistance power of patients during operation, and after operation, radiotherapy and chemotherapy, improves the immunity of organisms of the patients, controls the acute inflammation, protects the function of intestinal mucosal barrier, reduces complication, shortens hospital days and reduces treatment price.

The invention relates to a clinic detection marker of an inflammatory bowel disease, and applications thereof, and concretely relates to a molecular marker-Erbin gene in the inflammatory bowel disease, and an application of an inhibitor chloroquine of a downstream autophagy pathway regulated by the marker. An experiment result shows that the intestinal mucosa damage of DSS induced Erbin<+/+> and Erbin<-/-> mice injected with chloroquine are substantially reduced, the intestinal mucosa damage of the Erbin<-/-> mice is obviously severer than that of the Erbin<+/+> mice, and the mice injected with chloroquine have higher intestinal mucosa integrity, substantially lower inflammatory cell infiltration and substantially alleviated inflammatory bowel disease symptoms than mice not injected with the chloroquine, so the autophagy inhibitor chloroquine can improve the integrity of the intestinal mucosa and has a very good IBD inhibition effect, thereby the chloroquine has certain prevention and treatment effects on the inflammatory bowel disease.

The invention discloses a purpose and a use method of supported nanometer zinc oxide being adopted as intestinal health regulator of chickens. The purpose of the supported nanometer zinc oxide being adopted as the intestinal health regulator of the chickens is a composite material which adopts the kaolin or the montmorillonite or the attapulgite or the sepiolite as carrier to carry the supported nanometer zinc oxide. In the composite material of the supported nanometer zinc oxide, the weight percent of the zinc oxide is 10-50%. The use method of the supported nanometer zinc oxide being adopted as the intestinal health regulator of the chickens comprises a step of adding the zinc to the chicken feed according to the dose of 40-100 mg/kg. When the supported nanometer zinc oxide is used for feeding the chickens, the zinc oxide is slowly released in the intestinal tracts of animals, and more zinc oxide can reach to the intestinal tracts in molecular morphology to realize the control effect of the intestinal health. The supported nanometer zinc oxide which is added to the diet is obviously reduced, the daily gain of the chickens is increased, the intestinal morphology is improved, and the intestinal mucosal barrier is protected. Because the integrity of the intestinal tracts is improved, the damage of the chickens caused by clostridium is reduced.

The invention belongs to the field of biological medicines, relates to application of polygonatum sibiricum polysaccharides in preparation of medicines for treating ulcerative colitis, and in particular relates to application of polygonatum sibiricum polysaccharides in preparation of medicines for inhibiting release of inflammatory factors, regulating flora imbalance and repairing intestinal mucosal barrier injury. By adjusting the activity of neutrophil Myeloperoxidase (MPO), generation of inflammatory factors IL-6 and TNF-alpha is reduced, expression of an anti-inflammatory factor IL-10 is increased, inflammatory expression is inhibited, colon inflammation is improved by improving intestinal barrier, and potential application of polygonatum sibiricum polysaccharides in treatment of ulcerative colitis is expected to be explored.

The invention relates to proanthocyanidin products, a weaned piglet feed containing the proanthocyanidin products, and a preparation method and application of the feed. The weaned piglet feed comprises the following components in parts by weight: 0.01-0.05 part of the proanthocyanidin products, 50-75 parts of corn, 10-25 parts of dehulled soybean meal, 5-20 parts of puffed soybeans, 1-10 parts ofwhey powder, 2-4 parts of fish meal, 0-1.5 parts of wheat bran, 0-2 parts of soybean oil, 1-3 parts of calcium dihydrogen phosphate, 0-1.5 parts of glucose, 0.5-1 part of stone powder, 0-0.5 part of L-lysine, 0-0.1 part of DL-methionine and 0.5-2 parts of a vitamin mineral premix. The proanthocyanidin products and the weaned piglet feed can notably improve the antioxidant ability of piglets, contribute to relieving and repairing intestinal tract damage caused by weaning stress of the piglets, improve intestinal mucosal barrier functions, prevent and treat diarrhoea of the weaned piglets, reduce the death and culling rate and increase the breeding economic benefits.

The invention belongs to the field of food production, and particularly relates to an enteral nutrition preparation capable of protecting intestinal mucosal barrier function injured by chemotherapy. The nutrition preparation contains oyster polysaccharides. The oyster polysaccharides are prepared by the following steps: washing oyster meat, homogenating, adding water for performing ultrasonic treatment, adding protease for performing enzymolysis, then adding ethanol for precipitating to obtain oyster polysaccharides. The oyster polysaccharides component which have obvious activities of resisting oxidization, enhancing immunity and promoting proliferation of intestinal epithelial cells are screened through cell activity, are used as immune nutrients to be applied to enteral nutrition preparation, and are used for development of an enteral nutrition preparation capable of recovering and maintaining the intestinal mucosal barrier function injured by chemotherapy and improving prognosis of tumor patients. According to the enteral nutrition preparation, the nutrient substances are reasonably proportioned according to the physiological metabolism of the tumor patients so as to design and develop the enteral nutrition preparation which has the effects of recovering and maintaining the intestinal mucosal barrier function injured by chemotherapy and improving the prognosis of tumor patients.

The invention discloses a special type clinical nutrition formula for protecting intestinal mucosal barrier functions damaged after chemotherapy and a preparation method of the special type clinical nutrition formula. The special type clinical nutrition formula comprises the following components in parts by weight of 3-6 parts of fat, 25-45 parts of protein, 10-25 parts of carbohydrate, 12-25 parts of dietary fibers, 0.11-0.3 part of sodium, 0.1-0.2 part of calcium, 0.01-0.02 part of ferrum, 0.01-0.02 part of zinc, 0.01-0.02 part of magnesium, 0.02-0.3 part of composite vitamins, 0.5-5 parts of medical-edible homologous components, 0.1-0.4 part of probiotics, 0.1-1 part of natural plant compounds and 0.1-0.4 part of new resource foods. The clinical nutrition formula provided by the invention is in accordance with patients suffering from damaged intestinal mucosal barriers after chemotherapy, energy supply ratio of the carbohydrate, the protein and the fat is collocated, and multivitamins, minerals, the medical-edible homologous components and the new resource foods are selected, so that clinical symptoms of the patient can be alleviated, water and electrolyte metabolism disorder iscorrected, the nutrient state of the patient is improved, and the special type clinical nutrition formula is safe and free from toxic and side effects.

The invention discloses lactobacillus fermentum capable of regulating intestinal tract Claudin-1 and application of the lactobacillus fermentum, and belongs to the technical field of microorganisms. According to the lactobacillus fermentum CCFM1058 provided by the invention, the barrier function of intestinal mucosa can be effectively improved; compared with a colitis group, the lactobacillus fermentum CCFM1058 has the advantages that the expression level of the Claudin-1 protein gene is increased by nearly two times, and the colonic mucosal lesion is repaired. The level of lactobacillus fermentum CCFM1058 for improving the Claudin-1 is obviously better than that of a lactobacillus fermentum strain CECT5716 of a model strain. Therefore, the lactobacillus fermentum CCFM1058 with the function of regulating the Claudin-1 to protect the intestinal mucosa barrier has a wide application prospect in the fields of foods and microecological preparations.

A novel Akkermansia species has been isolated from fresh faeces obtained from the reticulated python. The species has been named Akkermansia glycaniphilus. It is capable of growing on mucus as a sole carbon and nitrogen source. The species can be used as a medicament, probiotic or cosmetic, e.g., for promoting weight loss, for promoting gut mucosal immune system function, for maintaining, restoring and/or increasing the physical integrity of the gut mucosal barrier, and for prevention or treatment of a variety of associated diseases or disorders.

The present invention relates to a medicine for treatment of cancer intestinal obstruction and a preparation method thereof. The medicine comprises the following components by weight: 30-90 parts of clove, 10-30 parts of cinnamon, 10-40 parts of raw rhubarb, 6-12 parts of borneol, and 20-40 parts of mirabilite. The present invention has the advantages that: through external application of the invention, the medicine has the effects of tonifying spleen and warming the middle, moving qi and directing qi downward, promoting digestion and removing food retention, clearing away heat and relaxing the bowel, relieving swelling and pain, resolving hard lump, and removing stagnate and inducing menstruation; can release intestinal adhesion, increase gastrointestinal motility, improve intestinal blood circulation, reduce capillary permeability, protect the intestinal mucosal barrier and reduce bacterial translocation, promote inflammation edema recession, and inhibit the growth of enteric bacilli, and finally achieve the functions of promoting fart and cacation, diminishing inflammation and swelling, relieving abdominal distension and pain, and restoring gastrointestinal function. Proved by clinical application, the medicine has remarkable clinical efficacy, is easy, economical and safe to use, is high in patient compliance and is worthy of promotion.

The invention relates to application of bacteroides fragilis to preparation of an enhancing agent for enhancing an intestinal mucosal barrier function. According to a great quantity of experiments, the bacteroides fragilis has functions of repairing intestinal epithelium mucus barrier and reducing intestinal mucosal permeability and is capable of effectively enhancing the intestinal mucosal barrier function to protect human health.

The invention aims to provide alcoholic beverage for protecting liver very well, namely functional low-damage healthcare wine, wherein xylitol and soybean oligosaccharides are added to edible wine, the concentration of xylitol is 0.1-40g/L, and the concentration of soybean oligosaccharides is 0.1-40g/L. The functional low-damage healthcare wine disclosed by the invention has the advantages that the wine contains various xylitols and soybean oligosaccharides with synergistic effects; by increase of the quantity of bifidobacterium and lactobacillus, gastrointestinal tract flora is regulated, and the micro ecological environment in the gastrointestinal tract is improved so that regular functions of the intestinal tract are maintained, and the shield of intestinal mucosa is protected from being damaged; and simultaneously, the synthesis of liver glycogen is also promoted, and hepatic cell nutrition and energy are supplemented so that the influence of alcohol on whole cells, especially hepatic cells, is reduced.

The invention discloses a traditional Chinese medicinal composition for treating infantile diarrhea. The traditional Chinese medicinal composition for treating the infantile diarrhea are prepared by extracting the following traditional Chinese medicine active ingredients in parts by weight: 50-250 parts of rhizoma atractylodis, 50-250 parts of poria cocos, 25-120 parts of baked ginger, 50-250 parts of fructus alpiniae oxyphyllae, 100-500 parts of roasted malt and 10-60 parts of fructus amomi. The invention also discloses a preparation method and application of the traditional Chinese medicinal composition for treating the infantile diarrhea. The traditional Chinese medicinal composition for treating the infantile diarrhea has the effects of treating the infantile diarrhea, protecting an intestinal mucosal barrier and regulating intestinal flora, and experimental study shows that the traditional Chinese medicinal composition for treating the infantile diarrhea has an obvious curative effect when being used for treating intestinal mucosal injury caused by the infantile diarrhea and chronic splenasthenic diarrhea and alteration of intestinal flora and is an ideal medicine for treating the intestinal mucosal injury caused by the infantile diarrhea and chronic splenasthenic diarrhea and alteration of intestinal flora.

The invention relates to the technical field of probiotics, in particular to a composition of lactobacillus paracasei LC-37 and application of the composition in reducing blood sugar. According to the invention, the lactobacillus paracasei LC-37 has new functions of promoting the secretion of the glucagon-like peptide 1, reducing blood sugar and relieving the symptoms of diabetes mellitus; the lactobacillus paracasei LC-37 is further compounded with the dietary fibers, the GLP-1 secretion promoting effect of the lactobacillus paracasei LC-37 is remarkably improved, and the composition of the lactobacillus paracasei LC-37 and the dietary fibers can remarkably reduce the blood glucose of diabetic animals, relieve oral glucose tolerance damage, reduce the insulin resistance index and regulate blood fat. The traditional Chinese medicine composition can improve intestinal mucosal barrier and pancreatic tissue damage, has a certain relieving effect on type II diabetes, and is safe, reliable and free of side effects.

The invention discloses a preparation method for a protective agent of an intestinal mucosal barrier. Butyric acid is absorbed or bonded on a silica gel surface or in a hole by using silica gel; and after being stirred and mixed, synthesized silica gel loading butyric acid and stearate are dried and pulverized. Because of having the characteristics of high surface activity, microporous structure and large specific surface area, the silica gel has good biocompatibility and intestinal mucosal affinity and a function of controlling slow release for the loaded butyric acid. In addition, the stearate reacts with the silica gel loading butyric acid in the process of stirring and mixing to generate byterate, and the stearate has an envelope function to add the storage stability of a product. The protective agent of the intestinal mucosal barrier can repair and protect intestinal epithelial cells, maintain the normal barrier of the intestinal mucosa and beneficial microorganism of the intestinal mucosa, and enhance health level of animals, daily gain and feed conversion efficiency.

The invention relates to the technical field of food. The composition for regulating and improving intestinal flora imbalance is prepared by mixing isomaltooligosacharide, inulin, lactitol, fructo-oligosaccharide, lactobacillus plantarum, stachyose, resistant dextrin, bifidobacterium lactis, bifidobacterium bifidum, lactobacillus acidophilus, bifidobacterium longum, bifidobacterium breve and lactobacillus rhamnosus. Compared with the prior art, the composition disclosed by the invention has the following beneficial effects that the composition disclosed by the invention starts from reasons such as constant value of probiotics in intestinal tracts and repair of intestinal mucosal barrier injury, and achieves the purpose of effectively regulating and improving diseases related to intestinal dysbacteriosis through mutual cooperation and synergistic effect of all the components; auxiliary materials such as cane sugar, maltodextrin, pigment and essence are not added, meanwhile, prebiotics and dietary fibers are added, colonization of probiotics in intestinal tracts is promoted, and the functional food is safe and reliable and can be used as functional food for improving intestinal flora disorder diseases after being eaten for a long time.

The invention discloses a traditional Chinese medicine preparation used for treating intestinal obstruction. The traditional Chinese medicine preparation is prepared from following main raw materials, by weight, 10 to 16 parts of pericarpium citri reticulatae viride, 5 to 12 parts of malt, 6 to 12 parts of magnolia obavata, 5 to 15 parts of folium sennae, 10 to 20 parts of ricinus communis, 3 to 8 parts of betel nut, 4 to 8 parts of szechwan Chinaberry fruit, 10 to 20 parts of pericarpium citri reticulatae, 8 to 16 parts of semen raphani, 9 to 13 parts of black soya bean, 5 to 15 parts of hawthorn, 1 to 5 parts of Sedum aizoon, and 4 to 6 parts of cortex cinnamomi. The traditional Chinese medicine preparation is capable of invigorating spleen and warming the middle warmer, activating qi for lowering adverse qi, removing food retention and promoting purgation, purgating heat and bowels, relieving swelling and pain, resolving hard lump, removing blood stasis and stimulating the menstrual flow, relieving intestinal adhesion, promoting gastrointestinal motility, improving intestinal blood circulation, reducing capillary permeability, protecting intestinal mucosal barrier and reducing bacterial translocation, and promoting inflammatory edema extinction. It is confirmed by clinical experiments that curative effect is excellent, application is convenient, economical, and safe; patient compliance is high; and the traditional Chinese medicine preparation is worthy of clinical expansion.

The invention relates to an intestinal flora reconstruction method. By the aid of antibiotic pretreatment and probiotic intervention, intestinal flora reconstruction is promoted, intestinal permeability is reduced to enhance intestinal mucosal barriers, and bile acid components are changed to play a certain role in improvement of glucose metabolism.

The invention discloses a nutritional double-mixture and a preparation method thereof. The nutritional double-mixture comprises a first nutritional agent and a second nutritional agent; the first nutritional agent and the second nutritional agent are combined according to the weight ratio of 8:1-12:1; after combination, the nutritional double-mixture comprises the following nutritional components in parts by weight: 160-200 parts by weight of carbohydrates, 70-90 parts by weight of fat, 80-100 parts by weight of protein, 5-7 parts by weight of micronutrients, and 40-55 parts by weight of dietary fiber, wherein the fat comprises saturated fatty acid, monounsaturated fatty acid and polyunsaturated fatty acid, and the polyunsaturated fatty acid comprises n6 polyunsaturated fatty acids and n3 polyunsaturated fatty acids in a weight ratio of 1:1. The energy ratio of the carbohydrates, fat and protein is reasonable, the ratio of various fatty acids in the fat is reasonable, the ratio of the n6 polyunsaturated fatty acids to the n3 polyunsaturated fatty acids is balanced, sufficient micronutrients and dietary fibers can be provided, inflammatory response can be effectively reduced, and intestinal mucosal barriers can be protected favourably.

The invention belongs to the fields of health-care food and food science and technology, and in particular, relates to an application of chitooligosaccharide in regulating animal intestinal disorders.The chitooligosaccharide is found out to be able to regulate the intestinal flora disorders caused by obesity or diabetes, promote the growth of beneficial bacteria such as intestinal lactobacillus and bifidobacterium, improve the intestinal mucosal barrier and significantly inhibit the proliferation of harmful bacteria such as vibrio desulfurizans. The invention provides an application method ofmaking chitooligosaccharide into clinically accepted pharmaceutical preparations or health-care food by a conventional process. The chitooligosaccharide has positive application value for preparing drugs for preventing and treating intestinal disorders of diabetes, obesity and intestinal inflammation.

The invention discloses applications of a Valeriana jatamansi Jones extract in preparation of drugs for restoring damaged small intestine villi or relieving intestinal mucosal barrier damage. The preparation method of the Valeriana jatamansi Jones extract comprises: taking Valeriana jatamansi Jones, carrying out room temperature leaching with ethanol having a volume percentage concentration of 95%, and concentrating the leaching solution to obtain an extract; dissolving the extract by using ethyl acetate; and filtering, and drying the obtained filtrate to obtain the product. According to the present invention, the obtained Valeriana jatamansi Jones extract can restore damaged small intestine villi or relieve intestinal mucosal barrier damage.

The invention discloses application of IAA in preparation of a medicine for preventing or treating inflammatory bowel diseases, belonging to the technical field of medicines. Experiments prove that IAA can significantly inhibit the occurrence and development of experimental colitis, effectively relieve colitis related symptoms, relieve weight loss, disease activity index (DAI) up-regulation, colon and spleen swelling and other symptoms of experimental animals caused by colitis, can also obviously regulate the increase of the contents of myeloperoxidase (MPO) and related inflammatory factors (TNF-alpha and IL-1beta) and the reduction of the content of an anti-inflammatory factor (IL-10) in a colitis state, and can restore the integrity of the structure and the function of the intestinal mucosal barrier and correct the imbalance of intestinal homeostasis in an animal body by increasing the expression of intestinal mucosal barrier integrity related proteins (ZO-1 and Occludin), thereby achieving the purpose of preventing and treating inflammatory bowel diseases.